| Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage … ND James, MR Sydes, NW Clarke, MD Mason, DP Dearnaley, MR Spears, ... The Lancet 387 (10024), 1163-1177, 2016 | 2106 | 2016 |
| Abiraterone for prostate cancer not previously treated with hormone therapy ND James, JS de Bono, MR Spears, NW Clarke, MD Mason, ... New England Journal of Medicine 377 (4), 338-351, 2017 | 1786 | 2017 |
| Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial CC Parker, ND James, CD Brawley, NW Clarke, AP Hoyle, A Ali, ... The Lancet 392 (10162), 2353-2366, 2018 | 1102 | 2018 |
| Addition of docetaxel to hormonal therapy in low-and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial NW Clarke, A Ali, FC Ingleby, A Hoyle, CL Amos, G Attard, CD Brawley, ... Annals of Oncology 30 (12), 1992-2003, 2019 | 374 | 2019 |
| Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol MR Sydes, MR Spears, MD Mason, NW Clarke, DP Dearnaley, ... Annals of Oncology 29 (5), 1235-1248, 2018 | 272 | 2018 |
| Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised … G Attard, L Murphy, NW Clarke, W Cross, RJ Jones, CC Parker, ... The lancet 399 (10323), 447-460, 2022 | 245 | 2022 |
| STAMPEDE investigators. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive … ND James, MR Sydes, NW Clarke, MD Mason, DP Dearnaley, MR Spears, ... Lancet 387 (10024), 1163-1177, 2016 | 217 | 2016 |
| Failure-free survival and radiotherapy in patients with newly diagnosed nonmetastatic prostate cancer: data from patients in the control arm of the STAMPEDE trial ND James, MR Spears, NW Clarke, DP Dearnaley, MD Mason, CC Parker, ... JAMA oncology 2 (3), 348-357, 2016 | 211 | 2016 |
| Abiraterone in “high-” and “low-risk” metastatic hormone-sensitive prostate cancer AP Hoyle, A Ali, ND James, A Cook, CC Parker, JS De Bono, G Attard, ... European urology 76 (6), 719-728, 2019 | 186 | 2019 |
| An introduction to the study of education D Matheson Routledge, 2014 | 141* | 2014 |
| Systemic Therapy for Advanced or Metastatic Prostate cancer: Evaluation of Drug Efficacy (STAMPEDE) investigators. Radiotherapy to the primary tumour for newly diagnosed … CC Parker, ND James, CD Brawley, NW Clarke, AP Hoyle, A Ali, ... Lancet 392 (10162), 2353-2366, 2018 | 125 | 2018 |
| How well prepared are medical students for their first year as doctors? The views of consultants and specialist registrars in two teaching hospitals C Matheson, D Matheson Postgraduate Medical Journal 85 (1009), 582-589, 2009 | 119 | 2009 |
| Combining enzalutamide with abiraterone, prednisone, and androgen deprivation therapy in the STAMPEDE trial G Attard, MR Sydes, MD Mason, NW Clarke, D Aebersold, JS de Bono, ... European urology, 2014 | 79 | 2014 |
| Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab S Lin, NA Kennedy, A Saifuddin, DM Sandoval, CJ Reynolds, RC Seoane, ... Nature communications 13 (1), 1379, 2022 | 76 | 2022 |
| Lifelong learning and lifelong education: A critique D Matheson, C Matheson Research in Post‐Compulsory Education 1 (2), 219-236, 1996 | 71 | 1996 |
| Adding celecoxib with or without zoledronic acid for hormone-naïve prostate cancer: long-term survival results from an adaptive, multiarm, multistage, platform, randomized … MD Mason, NW Clarke, ND James, DP Dearnaley, MR Spears, ... Journal of clinical oncology 35 (14), 1530-1541, 2017 | 63 | 2017 |
| Management of patients with advanced prostate cancer. Part I: intermediate-/high-risk and locally advanced disease, biochemical relapse, and side effects of hormonal treatment … S Gillessen, A Bossi, ID Davis, J de Bono, K Fizazi, ND James, N Mottet, ... European urology 83 (3), 267-293, 2023 | 62 | 2023 |
| Management of patients with advanced prostate cancer—metastatic and/or castration-resistant prostate cancer: report of the Advanced Prostate Cancer Consensus Conference (APCCC … S Gillessen, A Bossi, ID Davis, J de Bono, K Fizazi, ND James, N Mottet, ... European journal of cancer 185, 178-215, 2023 | 58 | 2023 |
| Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trial CC Parker, ND James, CD Brawley, NW Clarke, A Ali, CL Amos, G Attard, ... PLoS medicine 19 (6), e1003998, 2022 | 58 | 2022 |
| Quality of life in men with prostate cancer randomly allocated to receive docetaxel or abiraterone in the STAMPEDE trial HL Rush, L Murphy, AK Morgans, NW Clarke, AD Cook, G Attard, ... Journal of Clinical Oncology 40 (8), 825-836, 2022 | 53 | 2022 |
